Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS' Opdivo/Yervoy OK'd; 1st U.S. Immuno-Oncology Combo

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibb on Oct. 1 revealed it had gained the FDA's blessing under an accelerated approval to market Opdivo (nivolumab) plus Yervoy (ipilimumab) to treat patients with BRAF V600 wild-type unresectable or metastatic melanoma – the first immuno-oncology combination regimen approved in the U.S. in cancer.

Advertisement

Related Content

Another Opdivo Disappointment For BMS, This Time In Kidney Cancer

Topics

Advertisement
UsernamePublicRestriction

Register

SC029931

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel